Global Business Reports


Margarita Todorova, Jason Spizer

United States Pharmaceuticals & Biopharmaceuticals 2021

July 28, 2021

For many years, the life science industry has had breakthrough ideas bubbling under the surface, but accepted truths are difficult to change. For example, people took it as a given that it takes years to develop a vaccine, that virtual medicine will never scale for doctors or patients, and the regulatory system cannot adapt to innovation quickly enough to support lasting change. Over the past year, the US bio ecosystem turned this orthodoxy on its head, responding heroically, and faster than ever before in so many ways.

The rapid pace at which industry moved was enabled by decades of research by industry and academia, which formed the base for a mobilization never seen in the life sciences. Thanks to America’s pharma and biopharma industry, supported by a university system that is the envy of the world, as well as tech transfer, large pharma, fast-growing biotech, manufacturing, a well functioning incubator system, and an abundance of talent, skills and know-how regarding discovery, clinical trials and commercialization, the world now has life-saving drugs that will help end the COVID-19 pandemic and many more life-threatening diseases in the future.


“As always, this year’s GBR report shone a light on the important accomplishments of the biopharmaceutical industry and like the industry, that saved the world despite the encumbrances of the pandemic, GBR overcame its own constraints and has delivered a compelling report in a virtual format.” - Debbie Hart, President & CEO, BioNJ

The Global Business Report is a unique collection of perspectives across the industry and represents a timely outlook for the year ahead to help advise corporate strategy, innovation and critical investments. These provoking viewpoints from experts in the field help business leaders make informed decisions and provide invaluable insights. I personally look forward to each year’s release knowing I will be impressed with the high-quality content and learn something new. The team at GBR is a pleasure to work with and on behalf of EY, we look forward to partnering with you again in the future.” Arda Ural, PhD, EY Americas Industry Markets Leader, Health Sciences and Wellness

“I always look forward to the GBR publications on the life sciences sector. Irrespective of the area discussed- whether it is evolving market trends, emerging scientific platforms, or capital inflow into the industry- GBR always presents a well-researched and professionally compiled report that can be used as an excellent reference. Interviews with Industry leaders augment the content significantly providing a very practical view on current developments. GBR  is certainly a brand that I have learnt to trust, and one that I use as a basis to develop future strategies and action plans.” - Ramesh Subramanian, COO, Aragen Life Sciences

“We really enjoyed working with GBR. They do a good job of eliciting strong responses from their interviewees that provide perspective investors with a great overview of their own companies as to why people should invest. GBR also focuses on key companies that allow an investor to attain a broad view of the marketplace with a variety of different investment opportunities depending on their field of interest.” - James Sapirstein, Pesident and CEO, AzurRx BioPharma

“It is such a pleasure to work with the team at GBR. They are professional and supportive. I sincerely appreciate the efficient, gracious collaboration, the level of detail and accountability  demonstrated on our project, and the way they conduct business as a whole. I could not be more satisfied with the work, and we look forward to continuing this relationship.” - Jeff Reingold, COO, Contract Pharmacal Corp.

“I am honoured to have had the chance to work with GBR for the past couple of years. The questions posed by the journalists are well researched and thoughtful. The GBR’s editing is careful to present perspectives that are insightful and informative. The topics presented in this year’s report are timely and relevant. I believe the GBR is therefore useful to both active participants in the pharmaceutical industry as well as casual observers.” - James Gale, Founding Partner, Signet Healthcare Partners

“I was pleased to collaborate with GBR and its journalists on the 2021 U.S. Pharmaceuticals & Biopharmaceuticals report. We appreciated the opportunity to share Insmed’s perspective on rare disease drug development alongside a strong lineup of industry peers. The final report provided a comprehensive look at the strength and significant opportunities ahead for our industry.” – Will Lewis, Chair & CEO, Insmed

“The information provided by GBR is timely, accurate and factual. I enjoy reading the reports and learning new insights on topics closely related to our business. Highly recommended.” - Jose Antonio Moreno Toscano, CEO, LFB USA

“The Global Business Reports is a great asset to the healthcare and biotech community.  It was a pleasure to be interviewed by the editorial team.  The questions asked were well thought out and created a great framework in which to articulate both the business and science aspects of our business.  It is wonderful to see what others executives are striving for as we collectively work to shape the future of healthcare.” - Jay Roberts, CEO, Vyant Bio, Inc.

“GBR’s 2021 Pharmaceutical and Biopharmaceutical Industry Report is an insightful resource for our industry and Karyopharm is proud to be a partner in GBR’s work. The COVID-19 pandemic has tested our industry and this report demonstrates our collective focus to serve patients, regardless of the challenges we face.” - Michael G. Kauffman, MD, PhD, Co-Founder and former CEO of Karyopharm Therapeutics

“It was a pleasure to collaborate with the GBR journalist team in the preparation of the United States Pharmaceuticals & Biopharmaceuticals 2021 edition . The interview was clearly very professionally conducted by GBR seasoned journalist, providing an accurate and informative overview of our industry, exploring different and interesting angles and offering valuable insights about the future.” - Jorge Nogueira, CEO, Dipharma Francis

“If you’re looking for a great resource to learn up to date and first-hand information for global business decision makers, Global Business Reports is where you should be allocating your time. I had the pleasure of collaborating with GBR for the 2021 US Pharmaceuticals & Biopharmaceuticals report and the team was great to work with and the finished report was thorough and informative. I look forward to working with the team again in the future.” - John Patrick Oroho, Executive Vice President and Chief Strategy Officer, Porzio Life Sciences


SaudiVax provides an insight into the nascent biotech industry in Saudi Arabia.
Espee Group speaks about how the demand for drugs is changing.
Novan explains its vision to be the world’s leading nitric oxide-based science, technology and clinical translation company.
InteRNA Technologies explains the promise of microRNA therapeutics.


Western USA Mining 2024

GBR's Western USA Mining 2024 report offers a comprehensive overview of the current state of the mining industry and what Washington and all stakeholders across the mining value chain are doing to achieve mineral independence.



"We believe technology should enhance, not replace, the role of geologists in exploration."